Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
Completed
RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa. It is not yet known if epoetin alfa is more effective with or without dexamethasone in treating anemia-related fatigue in patients with prostate cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa and dexamethasone to see how well they work compared to epoetin alfa alone in... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2023
Locations: St. Joseph Mercy Cancer Center at St. Joseph Mercy Hospital, Ann Arbor, Michigan +10 locations
Conditions: Anemia, Fatigue, Prostate Cancer
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well... Read More
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
06/14/2023
Locations: Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan +12 locations
Conditions: Leukemia
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Completed
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2023
Locations: Henry Ford Medical Center - New Center One, Detroit, Michigan +4 locations
Conditions: Multiple Myeloma
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Completed
This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2023
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Smoldering Myeloma, Smoldering Multiple Myeloma
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Terminated
This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop abnormal cells from growing. Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide and bortezomib togethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2023
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Light Chain Deposition Disease, Primary Systemic Amyloidosis
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography
Active Not Recruiting
This pilot research trial studies the effects of dexamethasone in patients with non-small cell lung cancer that has not responded after previous treatment. Drugs such as dexamethasone can affect how tumors grow and respond to treatments. Imaging tests, such as fluoro-L-thymidine (FLT) positron emission tomography , use a small amount of radioactive substance to show changes in tumor cells. Studying the effects of dexamethasone on lung tumors using FLT positron emission tomography may help doctor... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/04/2023
Locations: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Active Not Recruiting
This randomized phase II trial studies how well ixazomib and dexamethasone or ixazomib, dexamethasone, and lenalidomide work based on the presence of the rearrangement of a gene called nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (NFKB2) in treating patients with multiple myeloma that has returned after a period of improvement or does not respond to treatment. Ixazomib may stop the growth of cancer cells by blocking enzymes called proteasomes needed for cell growth. Drugs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/04/2023
Locations: University of Michigan/Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different regimens of combination chemotherapy to see how well they work in treating children with acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
04/04/2023
Locations: Children's Hospital of Michigan, Detroit, Michigan +2 locations
Conditions: Leukemia
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of chemotherapy is more effective for acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing four regimens of combination chemotherapy to see how well they work in treating children with newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/04/2023
Locations: Children's Hospital of Michigan, Detroit, Michigan +2 locations
Conditions: Leukemia
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
Completed
The Phase 1 primary objectives of this study were to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants with relapsed or refractory multiple myeloma. This study also assessed the safety profile and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive multiple myeloma. The Phase 2 primary obj... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/16/2023
Locations: University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 170007, Ann Arbor, Michigan
Conditions: Relapsed/Refractory Multiple Myeloma
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Completed
This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, may interfere with the ability of cancer cells to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2023
Locations: West Michigan Cancer Center, Kalamazoo, Michigan
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Terminated
Multiple myeloma (MM) accounts for more than 10% of all blood cancers and 1% of all cancers. The purpose of this study is to assess how safe lemzoparlimab is and how lemzoparlimab moves through the body of adult participants with MM when given with or without dexamethasone, and in combination with other anti-myeloma regimens. Adverse events and change in disease activity will be assessed. Lemzoparlimab is an investigational drug being developed for the treatment of relapsed/refractory (R/R) MM.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 229309, Ann Arbor, Michigan +1 locations
Conditions: Multiple Myeloma